In this episode of Idea Collider, we sit down with Susan Galbraith from AstraZeneca, a leading figure in oncology R&D. Susan shares her journey from medical training in Manchester and Cambridge to spearheading transformative cancer treatments at AstraZeneca. She discusses pivotal moments in her career, AstraZeneca's vision for eliminating cancer as a cause of death, the role of patient stories in motivating R&D efforts, and the integration of emerging technologies like AI and digital health tools.

With a focus on collaboration and continuous learning, Susan provides insights into how successful oncology drugs are developed and the importance of equitable representation in clinical trials. Stay tuned for an engaging conversation that highlights the future of personalized cancer therapies and the collaborative efforts driving innovations in oncology.

Chapter Summaries;

00:00 Introduction and Guest Welcome

00:27 Susan Galbraith's Career Journey

02:37 Defining Success in Oncology R&D

05:01 Early Phase Drug Development

07:09 Digital Health and Patient Experience

12:37 Global Collaboration and Innovation

15:05 AI and Future of Oncology

28:08 Diversity and Inclusion in Clinical Trials

33:46 Mentorship and Career Advice

37:45 Challenges and Future Outlook in Oncology

42:06 Closing Remarks and Call to Action

Don't forget to Like, Share, Subscribe, Rate, and Review!

Keep up with Susan Gabraith;

• LinkedIn: https://www.linkedin.com/in/susan-galbraith-584a195/?originalSubdomain=uk

Follow Mike Rea On;

• Website: https://www.ideapharma.com/
• X: https://x.com/ideapharma
• LinkedIn: https://www.linkedin.com/in/bigidea/

Listen to more fantastic podcast episodes: https://podcast.ideapharma.com/

In this episode of IDEA Collider, we dive into the world of biotech innovation with John Maraganore, former CEO of Alnylam Pharmaceuticals. Recognized as a trailblazer, John transformed RNA interference from a scientific concept into a revolutionary class of medicines, leading the development of five life-changing drugs.

Join us as we explore John's journey from a first-generation American with Greek immigrant parents to a key figure in biomedicine. We'll discuss his education at the University of Chicago, his leadership role at Alnylam, drug delivery challenges for RNAi therapeutics, and the importance of strategic pharmaceutical alliances. John also shares his take on the current biotech environment, the impact of policy and regulation, and the promising future of genetic medicines and AI in drug discovery.

Chapter Summaries;

00:00 Introduction to John Maraganore: Biotech Trailblazer

01:11 John's Early Life and Education

03:09 Joining Alnylam and the RNAi Revolution

04:56 Challenges and Successes at Alnylam

06:47 Current Biotech Funding Environment

08:17 Global Competition and US Leadership in Biotech

10:25 The Importance of In-Person Collaboration

12:01 Overcoming Drug Delivery Hurdles

15:21 Maintaining an Entrepreneurial Spirit in Biotech

17:00 Balancing Science and Business in Decision Making

20:27 Strategic Partnerships in Biotech

23:36 The Role of Biotech in Global Challenges

26:25 Advocating for Policy Changes in Biotech

30:41 Mentoring the Next Generation of Biotech Leaders

32:35 Future Frontiers in Biotech Innovation

36:08 John's Vision for the Future of Biomedicine

37:18 Communicating Innovation and Leadership

Don't forget to Like, Share, Subscribe, Rate, and Review!

Keep up with John Maraganore;

• LinkedIn: https://www.linkedin.com/in/john-maraganore/

Follow Mike Rea On;

• Website: https://www.ideapharma.com/
• X: https://x.com/ideapharma
• LinkedIn: https://www.linkedin.com/in/bigidea/

Listen to more fantastic podcast episodes: https://podcast.ideapharma.com/

Welcome to another incredible episode of the IDEA Collider│Pharma Book Club series with your host Mike Rea. Today, Annie Duke joins us on the show to discuss her latest book, “Quit: The Power of Knowing When to Walk Away.” Annie is an Author, Professional Speaker, Decision Strategist & co-founder of The Alliance for Decision Education, a non-profit whose mission is to improve lives by empowering students through decision skills education.

In the episode, Annie Duke delves into the motivation behind her latest book, “Quit,” when quitting is a valuable option rather than sticking around, grit versus willingness to quit, and Stewart’s Butterfield’s Quit story before founding Slack. In addition, Annie expounds on the fear of changing your mind and why most people worry about failing instead of winning.

Ultimately, she delves into the Monkey & Pedestal Model, three reasons behind building the pedestal, the kill criteria & why you should have a quitting coach!

Tune in for more!

During this episode, you will learn about;

[00:00:33] Introducing today’s guest

[00:01:37] What motivated Annie in writing her book Quit as opposed to Thinking in Bets that lead to decision making

[00:06:40] The difference between grit & willingness to quit

[00:09:27] Why eight times more people die on the descent of Mt. Everest than climbing

[00:18:53] Muhammad Ali is the embodiment of showing how in one circumstance, Grit can be a virtue & in the other circumstance, a downfall

[00:30:20] Stewart Butterfield’s story from one of the world’s greatest quitter to founding Slack

[00:39:37] The fear of changing your mind & failing

[00:48:36] The monkey & pedestal model

[00:56:18] Three reasons behind building the pedestal

[01:02:38] The kill criteria & the idea of having a quitting coach

[01:10:08] Does Annie act as a quitting coach?

[01:18:51] The Reverse Sicilian concept

[01:20:17] How to connect with Annie Duke

Don’t forget to Follow, Rate, Review, Like, and Share

Mentioned Books

• Thinking in Bets by Annie Duke
• Quit: The Power of Knowing When to Walk Away by Annie Duke
• Grit by Angela Duckworth
• Into Thin Air by Jon Krakauer

Let’s Connect!

Follow Alliance For Decision Education;

• Website: https://alliancefordecisioneducation.org/

Follow Annie Duke;

• Website: https://www.annieduke.com/
• Twitter: https://twitter.com/AnnieDuke
• LinkedIn: https://www.linkedin.com/in/annie-duke/

More Products

Follow Mike Rea on;

• Website: https://www.ideapharma.com/
• Twitter: https://twitter.com/ideapharma
• LinkedIn: https://www.linkedin.com/in/bigidea/

To listen to more amazing podcast episodes: https://podcast.ideapharma.com/

Welcome to another incredible episode of the IDEA Collider series with your host Mike Rea. Today the Chief Financial Officer at Recursion, Dr. Michael Secora, joins us on the show as we discuss the industrial revolution of drug discovery. Michael is a scientist and a former equity investor.

In the episode, Michael delves into the reasons behind the incredibly fast growth at Recursion, the company’s mission of decoding biology to radically improve lives, the relatability of data, and how Recursion builds its various data sets for drug discovery. Moreover, he expounds on how Recursion stands out against its competitors in the tech industry, the unique demographics of the Recursion team, and what differentiates Recursion from other AI discovery companies.

Tune in!

During this episode, you will learn about;

[00:23] Introducing today’s episode

[01:29] About Michael Secora and Recursion as it is today

[04:58] Recursion’s Mission on decoding biology to improve lives radically

[08:48] Biotechnology versus BioPharma Companies

[15:00] Relatability of Data

[17:10] Recursion’s data sets & their contents

[22:13] How many terabytes of data are they in executing each experiment

[24:15] How Recursion stands out against competitors in the Tech environment

[26:23] Michael’s approach to humility in the pharmaceutical industry

[28:28] Demographics of the Recursion team

[31:20] Recursion’s Hack Week

[34:51] The difference between AI discovery companies & Recursion

[40:11] A hint of Recursion incredible speed in delivering value proposition

[47:47] Michael’s Book Recommendations

[50:16] How to connect with Michael & Recursion`

Don’t forget to Follow, Rate, Review, Like, and Share!

Mentioned Books

• Journey through Mathematics by Enrique A. Gonzalez
• Team of Teams by Gen. Stanley McChrystal, Tantum Collins, David Silverman & Chris Fussel
• What is Life by Schrodinger

Let’s Connect!

Follow Recursion on;

• Website: https://www.recursion.com/
• LinkedIn: https://www.linkedin.com/company/recursion-pharmaceuticals/

Follow Michael Secora

• LinkedIn: https://www.linkedin.com/in/michael-secora-phd/

More Products

Follow Mike Rea on;

• Website: https://www.ideapharma.com/
• Twitter: https://twitter.com/ideapharma
• LinkedIn: https://www.linkedin.com/in/bigidea/

To listen to more amazing podcast episodes: https://podcast.ideapharma.com/

The healthcare industry is moving towards a digital revolution. With the help of digital technology, healthcare providers can now provide better and more efficient services to their patients. Digital technology has also proven to have a positive impact on patient outcomes, as well as the cost of care.

Companies such as Openwater, which focuses on creating the future of medical imaging, have been able to deliver life-saving technologies. Through the use of low-intensity ultrasound, Openwater has been able to treat diseases such as glioblastoma, depression, neurodegenerative diseases, and stroke.

In this episode, Mary Lou Jepsen, the CEO and Founder of Openwater shares how Openwater started and what it deals with. Mary Jepsen also shares how her company has transformed healthcare through digital technology. Moreover, she discusses the operating and hiring principles of the company.

Tune in for more insights!

Key Highlights

[01:44] Meet our guest; Meet our guest; Mary Lou Jepsen, and hear her backstory

[03:32] The contrast between Pharmaceutical Companies and companies such as Google & Facebook

[05:18] How we can apply physics to create interference ability and be able to see into our bodies using camera chips used in smartphones instead of using huge and expensive MRI scanners

[07:32] Why the One Laptop Per Child (OLPC) initiative didn’t work

[09:35] How she co-created the world’s first holographic video system from an idea that seemed impossible

[12:07] Physicists’ predominant culture of looking for all the ways that they might be wrong and learning from that vs. Biologists’ culture of looking for any proof that they are right

[17:05] Technology that uses low-intensity ultrasound on human brain organoids in glioblastoma cancer treatment which is better than chemotherapy

[18:24] How did Openwater start, and what does the company deal with?

[20:17] The use of technology to enable rapid identification of the large vessel occlusions to decrease the time to intervention in stroke victims

[26:56] Severe depression treatment using a headset capable of focusing low-frequency ultrasound on the nerve cells in the brain, which is more effective than transcranial magnetic stimulation

[31:42] The side effect of psychedelics in depression treatment

[37:00] Comparison between cost change in the consumer electronics industry and the healthcare industry

[40:21] The operating and hiring principles of the Openwater company

[49:00] How to link with Mary Lou Jepsen

Don’t forget to Follow, Rate, Review, Like, and Share!

Let’s Connect!

Follow Mary Lou Jepsen on her;

• Personal website:https://www.maryloujepsen.com/
• Company website: https://www.openwater.cc/
• LinkedIn: https://www.linkedin.com/in/majepsen/
• Twitter: https://twitter.com/mljmljmlj
• Facebook: https://web.facebook.com/maryloujepsen?_rdc=1&_rdr

More Products

Follow Mike Rea on;

• Website: https://www.ideapharma.com/
• Twitter: https://twitter.com/ideapharma
• LinkedIn: https://www.linkedin.com/in/bigidea/

To listen to more fantastic podcast episodes: https://podcast.ideapharma.com/

Welcome to another incredible episode of the IDEA Collider│Pharma Book Club series with your host Mike Rea. Today a competitive advantage expert, and CEO of Smart Advantage, Jaynie Smith, joins us on the show. She delves into snippets in her book, Creating Competitive Advantage, & the role of competitive advantage in increasing sales and protecting profit margins.

Moreover, she explains that it’s not about prices but your value proposition, understanding your customers' top three buying criteria, and competitive positioning. Ultimately she discusses the power of competitive advantage, implementing metrics that quantify competitive ads and focusing on the company rather than product advantage.

Tune in for more!

During this episode, you will learn about;

[00:20] Introducing today’s episode

[01:27] About today’s guest, “Jaynie Smith.”

[05:05] The process of unpacking & looking for opportunities

[09:44] Does everyone in business understand why they are in business

[11:45] Competitive advantage is closing deals & making money in an organization

[13:43] Why companies don’t spend enough time listening to their customers

[16:09] Building your value proposition

[22:28] Competitive positioning

[26:05] Do people give positioning the credit that’s due in the business world

[30:48] Do ad agencies get competitive positioning right?

[32:20] Company versus product competitive advantage

[35:57] Why companies lose sight of things that matter most to their customers

[38:52] Persistence in communication

[40:58] How to connect with Jaynie Smith

[41:40] Book recommendations from Jaynie

Let’s Connect!

Follow Jaynie Smith on;

• LinkedIn: https://www.linkedin.com/in/jayniesmith/
• Website: jayniesmith.com

Follow Smart Advantage

• Website: https://smartadvantage.com/

More Products

Follow Mike Rea on;

• Website: https://www.ideapharma.com/
• Twitter: https://twitter.com/ideapharma
• LinkedIn: https://www.linkedin.com/in/bigidea/

To listen to more amazing podcast episodes: https://podcast.ideapharma.com/